Catequentinib
Children
Cancer Institute and Hospital, Chinese Academy of Medical SciencesSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Children cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ERGOCALCIFEROLUM Chulalongkorn University | Phase 4 | B |
bay94-9027 Bayer | Phase 3 | B |
Damoctocog Alfa Pegol Bayer | Phase 3 | B |
dn-101 Chulalongkorn University | Phase 4 | B |
Nivolumab St. Petersburg State Pavlov Medical University | Phase 2 | B |
View all 16 →
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →